Financial Ratios Hansoh Pharmaceutical Group Company Limited
Equities
3692
KYG549581067
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.50 HKD | -1.25% |
|
+1.12% | +82.29% |
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | 8.59 | 7.55 | 5.7 | 5.31 | 7.54 | ||||
Return on Total Capital | 11.17 | 8.66 | 6.41 | 5.86 | 8.28 | ||||
Return On Equity % | 16.62 | 14.31 | 12.11 | 13.53 | 16.05 | ||||
Return on Common Equity | 16.62 | 14.31 | 12.11 | 13.53 | 16.05 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 90.76 | 91.24 | 90.73 | 89.78 | 90.89 | ||||
SG&A Margin | 44.44 | 44 | 44.21 | 41.97 | 36.77 | ||||
EBITDA Margin % | 34.4 | 31.74 | 31.25 | 29.94 | 34.89 | ||||
EBITA Margin % | 31.91 | 29.15 | 27.89 | 26.62 | 31.93 | ||||
EBIT Margin % | 31.91 | 29.15 | 27.79 | 26.52 | 31.83 | ||||
Income From Continuing Operations Margin % | 29.56 | 27.31 | 27.54 | 32.44 | 35.66 | ||||
Net Income Margin % | 29.56 | 27.31 | 27.54 | 32.44 | 35.66 | ||||
Net Avail. For Common Margin % | 29.56 | 27.31 | 27.54 | 32.44 | 35.66 | ||||
Normalized Net Income Margin | 21.64 | 19.83 | 20.18 | 23.14 | 25.74 | ||||
Levered Free Cash Flow Margin | -42.28 | 13.12 | 15.48 | 20.48 | 19.58 | ||||
Unlevered Free Cash Flow Margin | -42.26 | 13.45 | 15.87 | 20.89 | 19.61 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.43 | 0.41 | 0.33 | 0.32 | 0.38 | ||||
Fixed Assets Turnover | 4.11 | 3.44 | 2.71 | 3 | 3.76 | ||||
Receivables Turnover (Average Receivables) | 3.23 | 2.92 | 2.59 | 2.97 | 3.84 | ||||
Inventory Turnover (Average Inventory) | 2.25 | 2.46 | 2.03 | 2.02 | 1.82 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 6.43 | 7.67 | 9.86 | 4.21 | 10.18 | ||||
Quick Ratio | 6.3 | 7.52 | 9.64 | 4.11 | 9.9 | ||||
Operating Cash Flow to Current Liabilities | 0.89 | 0.85 | 1.05 | 0.45 | 1.43 | ||||
Days Sales Outstanding (Average Receivables) | 113.15 | 124.97 | 141.11 | 122.69 | 95.29 | ||||
Days Outstanding Inventory (Average Inventory) | 162.42 | 148.63 | 179.95 | 180.94 | 201.08 | ||||
Average Days Payable Outstanding | 84.41 | 69.28 | 94.6 | 60.72 | 58.58 | ||||
Cash Conversion Cycle (Average Days) | 191.17 | 204.32 | 226.46 | 242.91 | 237.78 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 0.52 | 19.11 | 19.33 | 16.68 | 0.41 | ||||
Total Debt / Total Capital | 0.52 | 16.05 | 16.2 | 14.3 | 0.41 | ||||
LT Debt/Equity | 0.46 | 19.06 | 19.26 | 0.4 | 0.21 | ||||
Long-Term Debt / Total Capital | 0.45 | 16 | 16.14 | 0.35 | 0.21 | ||||
Total Liabilities / Total Assets | 14.03 | 26.26 | 24.51 | 21.93 | 9.41 | ||||
EBIT / Interest Expense | 1.69K | 54.84 | 44.85 | 40.18 | 583.36 | ||||
EBITDA / Interest Expense | 1.82K | 59.99 | 50.77 | 45.68 | 643.36 | ||||
(EBITDA - Capex) / Interest Expense | 956.54 | 51.28 | 46.08 | 42.38 | 610.18 | ||||
Total Debt / EBITDA | 0.03 | 1.21 | 1.48 | 1.41 | 0.03 | ||||
Net Debt / EBITDA | -4.54 | -4.77 | -5.84 | -6.76 | -5.41 | ||||
Total Debt / (EBITDA - Capex) | 0.06 | 1.41 | 1.63 | 1.52 | 0.03 | ||||
Net Debt / (EBITDA - Capex) | -8.66 | -5.58 | -6.44 | -7.28 | -5.71 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 0.09 | 14.33 | -5.56 | 7.69 | 21.35 | ||||
Gross Profit, 1 Yr. Growth % | -0.74 | 14.94 | -6.1 | 6.57 | 22.85 | ||||
EBITDA, 1 Yr. Growth % | 0.85 | 5.5 | -4.93 | 3.18 | 41.41 | ||||
EBITA, 1 Yr. Growth % | -0.27 | 4.46 | -7.45 | 2.82 | 45.55 | ||||
EBIT, 1 Yr. Growth % | -0.27 | 4.46 | -7.56 | 2.76 | 45.64 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 0.48 | 5.61 | -4.76 | 26.85 | 33.39 | ||||
Net Income, 1 Yr. Growth % | 0.48 | 5.61 | -4.76 | 26.85 | 33.39 | ||||
Normalized Net Income, 1 Yr. Growth % | 1.02 | 4.73 | -3.9 | 23.5 | 35.01 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | -6.34 | 1.21 | -1.29 | 19.65 | 40.62 | ||||
Accounts Receivable, 1 Yr. Growth % | 39.25 | 17.54 | -2.66 | -10.18 | -1.38 | ||||
Inventory, 1 Yr. Growth % | -27.9 | 37.29 | 9.21 | 28.55 | 13.1 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 19.5 | 50.85 | -0.73 | -4.93 | -0.99 | ||||
Total Assets, 1 Yr. Growth % | 6.22 | 30.63 | 10.46 | 10.12 | -4.18 | ||||
Tangible Book Value, 1 Yr. Growth % | 37.01 | 12.01 | 13 | 13.28 | 11 | ||||
Common Equity, 1 Yr. Growth % | 37.04 | 12.05 | 13.07 | 13.9 | 11.18 | ||||
Cash From Operations, 1 Yr. Growth % | -28.21 | 7.81 | 6.37 | 13.69 | 23.93 | ||||
Capital Expenditures, 1 Yr. Growth % | 140.96 | -67.78 | -40.7 | -19.51 | 1.08 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | -207.64 | -135.47 | 15.68 | 42.45 | 16.01 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -207.61 | -136.38 | 15.53 | 41.77 | 13.92 | ||||
Dividend Per Share, 1 Yr. Growth % | - | 12.44 | 20.84 | 118.47 | 63.53 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 6.08 | 6.97 | 3.91 | 0.85 | 14.31 | ||||
Gross Profit, 2 Yr. CAGR % | 5.25 | 6.81 | 3.89 | 0.04 | 14.42 | ||||
EBITDA, 2 Yr. CAGR % | 11.89 | 3.15 | -0.96 | -0.96 | 20.79 | ||||
EBITA, 2 Yr. CAGR % | 11.28 | 2.07 | -2.86 | -2.45 | 22.33 | ||||
EBIT, 2 Yr. CAGR % | 11.28 | 2.07 | -3.03 | -2.54 | 22.33 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 16.18 | 3.01 | 0.29 | 9.91 | 30.08 | ||||
Net Income, 2 Yr. CAGR % | 16.18 | 3.01 | 0.29 | 9.91 | 30.08 | ||||
Normalized Net Income, 2 Yr. CAGR % | 14.93 | 2.86 | 0.32 | 8.94 | 29.13 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 7.17 | -2.64 | -0.05 | 8.68 | 29.71 | ||||
Accounts Receivable, 2 Yr. CAGR % | 8.73 | 27.93 | 6.97 | -6.49 | -5.88 | ||||
Inventory, 2 Yr. CAGR % | -21.08 | -0.51 | 22.45 | 18.49 | 20.58 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 29.12 | 34.26 | 22.37 | -2.86 | -2.98 | ||||
Total Assets, 2 Yr. CAGR % | 57.19 | 17.79 | 20.12 | 10.29 | 2.72 | ||||
Tangible Book Value, 2 Yr. CAGR % | 169.63 | 23.88 | 12.51 | 13.14 | 12.13 | ||||
Common Equity, 2 Yr. CAGR % | 169.13 | 23.91 | 12.56 | 13.48 | 12.53 | ||||
Cash From Operations, 2 Yr. CAGR % | 7.4 | -12.02 | 7.08 | 9.97 | 18.7 | ||||
Capital Expenditures, 2 Yr. CAGR % | 93.48 | -11.88 | -56.29 | -30.91 | -9.8 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | -3.43 | -38.21 | -37.12 | 28.37 | 28.55 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -3.44 | -37.43 | -36.33 | 27.98 | 27.09 | ||||
Dividend Per Share, 2 Yr. CAGR % | - | - | 16.57 | 62.48 | 89.01 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 12 | 8.76 | 2.62 | 5.15 | 7.26 | ||||
Gross Profit, 3 Yr. CAGR % | 11.23 | 8.39 | 2.32 | 4.77 | 7.13 | ||||
EBITDA, 3 Yr. CAGR % | 14.95 | 9.72 | -0.36 | 0.4 | 11.52 | ||||
EBITA, 3 Yr. CAGR % | 14.72 | 8.96 | -2.01 | -1.01 | 11.47 | ||||
EBIT, 3 Yr. CAGR % | 14.72 | 8.96 | -2.12 | -1.14 | 11.43 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 17.21 | 12.55 | 0.35 | 8.46 | 17.24 | ||||
Net Income, 3 Yr. CAGR % | 17.21 | 12.55 | 0.35 | 8.46 | 17.24 | ||||
Normalized Net Income, 3 Yr. CAGR % | 16.08 | 11.42 | 0.55 | 7.52 | 17.02 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 5.15 | -2.19 | 6.13 | 18.43 | ||||
Accounts Receivable, 3 Yr. CAGR % | 12.57 | 11.59 | 16.8 | 0.92 | -4.82 | ||||
Inventory, 3 Yr. CAGR % | -12.07 | -5.09 | 2.63 | 24.45 | 16.66 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 25.29 | 35.99 | 21.41 | 12.49 | -2.24 | ||||
Total Assets, 3 Yr. CAGR % | 52.4 | 47.79 | 15.3 | 16.69 | 5.24 | ||||
Tangible Book Value, 3 Yr. CAGR % | 58.23 | 101.19 | 20.14 | 12.76 | 12.42 | ||||
Common Equity, 3 Yr. CAGR % | 58.15 | 100.96 | 20.19 | 13 | 12.71 | ||||
Cash From Operations, 3 Yr. CAGR % | 19.46 | 7.54 | -6.28 | 9.24 | 14.44 | ||||
Capital Expenditures, 3 Yr. CAGR % | 77.25 | 6.45 | -22.78 | -46.42 | -21.57 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 206.81 | -30.84 | -24.78 | -17.42 | 24.11 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 206.78 | -30.26 | -24.16 | -16.86 | 23.11 | ||||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | 43.72 | 62.83 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 12.83 | 8.69 | 5.52 | 7.15 | ||||
Gross Profit, 5 Yr. CAGR % | - | 12.48 | 8.24 | 4.97 | 7 | ||||
EBITDA, 5 Yr. CAGR % | - | 11.48 | 8.3 | 4.85 | 7.61 | ||||
EBITA, 5 Yr. CAGR % | - | 11.03 | 7.33 | 3.74 | 7.09 | ||||
EBIT, 5 Yr. CAGR % | - | 11.03 | 7.26 | 3.66 | 7.01 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 12.95 | 10.12 | 11.49 | 11.33 | ||||
Net Income, 5 Yr. CAGR % | - | 12.95 | 10.12 | 11.49 | 11.33 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 11.9 | 9.5 | 10.42 | 11.13 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 6.55 | 9.5 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 16.36 | 10.29 | 3.97 | 7.13 | ||||
Inventory, 5 Yr. CAGR % | - | 3.04 | 0.39 | 3.72 | 9.46 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 27.09 | 24.11 | 18.87 | 10.99 | ||||
Total Assets, 5 Yr. CAGR % | - | 41.31 | 38.56 | 31.46 | 10.09 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 46.47 | 38.05 | 59.81 | 16.87 | ||||
Common Equity, 5 Yr. CAGR % | - | 46.44 | 38.04 | 59.9 | 17.07 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 15.63 | 14.35 | 8.5 | 3.01 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 14 | 1.25 | -10.45 | -17.83 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 62.75 | -12.08 | -6.8 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 63.56 | -11.73 | -6.76 |
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition